262 related articles for article (PubMed ID: 30516569)
1. Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma.
Jin Z; Holubek M; Sukov WR; Sattler CA; Wiktor AE; Jenkins RB; Wu TT; Yoon HH
Am J Clin Oncol; 2019 Feb; 42(2):190-195. PubMed ID: 30516569
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
4. Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas.
Fassan M; Ludwig K; Pizzi M; Castoro C; Guzzardo V; Balistreri M; Zaninotto G; Ruol A; Giacomelli L; Ancona E; Rugge M
Hum Pathol; 2012 Aug; 43(8):1206-12. PubMed ID: 22217477
[TBL] [Abstract][Full Text] [Related]
5. Primary esophageal adenosquamous carcinoma: a retrospective analysis of 24 cases.
Zhang HD; Chen CG; Gao YY; Ma Z; Tang P; Duan XF; Ren P; Yue J; Yu ZT
Dis Esophagus; 2014; 27(8):783-9. PubMed ID: 24127755
[TBL] [Abstract][Full Text] [Related]
6. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma.
König AM; Reeh M; Dancau AM; Rathjens M; Gros S; Uzunoglu FG; Bockhorn M; Simon R; Sauter G; Marx A; Izbicki JR
Anticancer Res; 2013 Nov; 33(11):4975-82. PubMed ID: 24222138
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
8. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
[TBL] [Abstract][Full Text] [Related]
9. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
10. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
11. Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry.
Alvarez-Manceñido F; Jimenez-Fonseca P; Carmona-Bayonas A; Arrazubi V; Hernandez R; Cano JM; Custodio A; Pericay Pijaume C; Aguado G; Martínez Lago N; Sánchez Cánovas M; Cacho Lavin D; Visa L; Martinez-Torron A; Arias-Martinez A; López F; Limón ML; Vidal Tocino R; Fernández Montes A; Alsina M; Pimentel P; Reguera P; Martín Carnicero A; Ramchandani A; Granja M; Azkarate A; Martín Richard M; Serra O; Hernández Pérez C; Hurtado A; Gil-Negrete A; Sauri T; Morales Del Burgo P; Gallego J
Gastric Cancer; 2021 Jul; 24(4):926-936. PubMed ID: 33651195
[TBL] [Abstract][Full Text] [Related]
12. [Adenocarcinoma of the gastro-esophageal junction].
Huang Q; Fan XS; Shi J; Zhang YF; Feng AN; Wu HY; Sun Q; Zhou Q; Yu HP; Meng FQ; Wang JM
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):793-5. PubMed ID: 23324225
[No Abstract] [Full Text] [Related]
13. Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study.
Dijksterhuis WPM; Verhoeven RHA; Meijer SL; Slingerland M; Haj Mohammad N; de Vos-Geelen J; Beerepoot LV; van Voorthuizen T; Creemers GJ; van Oijen MGH; van Laarhoven HWM
Gastric Cancer; 2020 Jul; 23(4):579-590. PubMed ID: 31927675
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
15. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
16. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
[TBL] [Abstract][Full Text] [Related]
17. Primary adenosquamous carcinoma of the esophagus.
Chen SB; Weng HR; Wang G; Yang JS; Yang WP; Liu DT; Chen YP; Zhang H
World J Gastroenterol; 2013 Dec; 19(45):8382-90. PubMed ID: 24363531
[TBL] [Abstract][Full Text] [Related]
18. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
19. Squamous/adenosquamous carcinoma of the gallbladder: Analysis of 34 cases and comparison of clinicopathologic features and surgical outcomes with adenocarcinoma.
Song HW; Chen C; Shen HX; Ma L; Zhao YL; Zhang GJ; Geng ZM; Wang L
J Surg Oncol; 2015 Nov; 112(6):677-80. PubMed ID: 26458491
[TBL] [Abstract][Full Text] [Related]
20. Adenosquamous carcinoma of the lung: surgical results as compared with squamous cell and adenocarcinoma cases.
Maeda H; Matsumura A; Kawabata T; Suito T; Kawashima O; Watanabe T; Okabayashi K; Kubota I;
Eur J Cardiothorac Surg; 2012 Feb; 41(2):357-61. PubMed ID: 21737295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]